PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
Abstract The relationship between severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) viral load reduction and disease symptom resolution remains largely undefined for coronavirus disease 2019 (COVID‐19). While the vaccine‐derived immunity takes time to develop, neutralizing monoclonal anti...
Saved in:
Main Authors: | C. Steven Ernest II (Author), Jenny Y. Chien (Author), Dipak R. Patel (Author), Emmanuel Chigutsa (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany
by: Bjoern Jensen, et al.
Published: (2021) -
501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
by: Haolin Liu, et al.
Published: (2021) -
Meropenem PK/PD Variability and Renal Function: "We Go Together"
by: Jacopo Angelini, et al.
Published: (2023) -
PK-PD integration of enrofloxacin and cefquinome alone and in combination against Klebsiella pneumoniae using an in vitro dynamic model
by: Yanzhe Wei, et al.
Published: (2023) -
PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
by: Laura Oggianu, et al.
Published: (2023)